26 / 30
PHASE III TRIALS COMPARISON: SAFETY
Preferred Term, %
Cabozantinib
(N=467)
Regorafenib
(N=374)
Ramucirumab
(N=197)
Any grade 3 or 4 adverse event
68
66
35
Palmar-plantar erythrodysesthesia
17
13
NA
Hypertension
16
15
13
AST increased
12
11
3
Fatigue
10
9
4
Diarrhoea
10
3
0
Decreased appetite
6
3
1.5
ALT increased
5
4
1
Anaemia
4
5
2.5